Abstract:Background Previous reports of long-term outcomes of TAVR focus on higher risk patients and suggest potential temporal changes. The indications of TAVR have expanded to low-risk patients. We aimed to evaluate the long-term and temporal performances of transcatheter aortic valve replacement (TAVR) compared to surgical aortic valve replacement (SAVR). Methods Randomized controlled trials reporting outcomes with at least 1-year follow-up were included. The primary outcome was the composite of all-cause death or disabling stroke. Results We included 8 trials with 8,749 patients. TAVR was associated with a higher risk of long-term (5-year) primary outcome compared to SAVR among higher-risk (odds ratio [OR], 1.25; 95% CI, 1.07–1.47) but not lower-risk participants (1.0 [0.77–1.29]). However, a significant temporal interaction was detected in both risk profiles. TAVR with balloon-expandable valves was associated with a higher risk of long-term primary outcome compared to SAVR (1.38 [1.2–1.6]), whereas no statistical difference was found with self-expanding valves (1.03 [0.89–1.19]). There was a significant interaction between the two valve systems, and a temporal interaction was detected in both systems. Overall landmark analysis revealed a lower risk in TAVR within the initial 30 days (0.76 [0.6, 0.96]), comparable between 30 days to 2 years (1.04 [0.85, 1.28]), and higher beyond 2 years (1.36 [1.15– 1.61]). Analysis for all-cause death generated largely similar results. Conclusions TAVR was associated with a higher long-term risk of primary outcome compared to SAVR in higher-risk patients and with balloon-expandable valves. However, a characteristic temporal interaction was documented in all subgroups. Future studies are warranted to test these findings. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement None. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: NA. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data are available upon reasonable request from Dr. Xinlin Zhang. * MVC : major bleeding, major vascular complication OR : odds ratio RCT : randomized controlled trials SAVR : surgical aortic valve replacement TAVR : Transcatheter aortic valve replacement TIA : transient ischemic attack PPM : permanent pacemaker implantation PVL : paravalvular leak.

Association between trajectories in cardiac damage and clinical outcomes after transcatheter aortic valve replacement

Impact of Early Changes in Cardiac Damage Following Transcatheter Aortic Valve Implantation.

Long-Term Impact of Cardiac Damage Following Transcatheter Aortic Valve Replacement

NT-proBNP trajectory after transcatheter aortic valve replacement and its association with 5-year clinical outcomes

Early evolution of cardiac damage staging following transcatheter aortic valve replacement: prevalence, clinical patterns and prognostic significance

891 EARLY EVOLUTION OF CARDIAC DAMAGE STAGING FOLLOWING TRANSCATHETER AORTIC VALVE REPLACEMENT: PREVALENCE, CLINICAL PATTERNS AND PROGNOSTIC SIGNIFICANCE

Outcome of aortic stenosis according to invasive cardiac damage staging after transcatheter aortic valve replacement

The impact of extra-valvular cardiac damage on mid-term clinical outcome following transcatheter aortic valve replacement in patients with severe aortic stenosis

Transcatheter Aortic Valve Replacement for Bicuspid Vs. Tricuspid Aortic Stenosis among Patients at Low Surgical Risk in China: from the Multicenter National NTCVR Database

Extent of Cardiac Damage and Mortality in Patients Undergoing Transcatheter Aortic Valve Implantation

Cardiac Damage Staging Predicts Outcomes in Aortic Valve Stenosis After Aortic Valve Replacement: Meta-Analysis

Extent of cardiac damage and hospitalization burden in patients undergoing transcatheter aortic valve replacement

Sex-Specific Differences in Upstream Cardiac Damage in Patients With Aortic Stenosis Undergoing TAVR

Impact of Right Ventricular Dysfunction and Tricuspid Regurgitation on Outcomes in Patients Undergoing Transcatheter Aortic Valve Replacement

Ascending Aortic Dilatation Rate after Transcatheter Aortic Valve Replacement in Patients with Bicuspid and Tricuspid Aortic Stenosis: A Multidetector Computed Tomography Follow-Up Study.

Long-term and Temporal Outcomes of Transcatheter Versus Surgical Aortic-valve Replacement in Severe Aortic Stenosis

Cardiac Damage and Conduction Disorders after Transcatheter Aortic Valve Implantation

Tricuspid regurgitation and in-hospital outcomes after transcatheter aortic valve replacement in high-risk patients

Meta-Analysis Comparing Results of Transcatheter Versus Surgical Aortic-Valve Replacement in Patients With <i>Severe</i> Aortic Stenosis

Long-term and Landmark Analysis of Transcatheter versus Surgical Aortic-Valve Replacement in Severe Aortic Stenosis

Impact of Tricuspid Regurgitation on Outcomes of Transcatheter Aortic Valve Replacement With Balloon-Expandable Valves